Perfil epidemiológico y clínico de pacientescon Síndrome de Sjögren del Departamento de Reumatología del Hospital de Clínicas- Proyecto Psecopy. Datos preliminares
Resumen
El síndrome de Sjögren es una enfermedad autoinmune sistémica caracterizada por la sequedad de mucosas y compromiso sistémico. El objetivo del presente estudio fue describir las características clínico epidemiológicas de los pacientes con Síndrome de Sjögren primario incluidos en la cohorte Psecopy que reúnan los criterios ACR/EULAR 2016 y que hayan acudido al Departamento de Reumatología del Hospital de Clínicas de San Lorenzo. Resultados: Se incluyeron 33 pacientes con Síndrome de Sjögren primario. De los cuales 31 (93,93%) pertenecían al género femenino y 2 (6,01%) al género masculino. Con una edad promedio al momento del diagnóstico de Sjögren primario de 46,12 años. Y un tiempo de duración de la enfermedad con una media de 2,10 años. Las comorbilidades más frecuentemente asociadas fueron la hipertensión arterial (21,21%) seguido del hipotiroidismo (18,18%). A estos pacientes se les realizó la biopsia salival por no cumplir criterios, en el 12,12 % de los pacientes según criterios de Chisholm y Mason, donde se encontró un focus score predominante de 3. En relación al ESSDAI se encontró un compromiso articular en 51,51 %, glandular en el 54,54 %, articular en 51,51%, pulmonar, linfadenopatía y domi nio biológico en un 12,12%, hematológico y dominio constitucional en un 9,09%, cutáneo y renal en un 6,06%, sistema nervioso central y periférico en un 3,03%. Se destaca también la baja actividad de la enfermedad en un 63,63%, moderada actividad en un 21,21% y alta actividad en un 15,15% según la escala de ESSDAI. No se encontraron neoplasias.
Descargas
Citas
(1) Kvarnström, M., Ottosson, V., Nordmark, B., Wahren-Herlenius, M. Incident cases of primary Sjögren syndrome during a 5-year period in Stockholm County: a descriptive study of the patients and their characteristics. Scandinavian journal of rheumatology. 2015; 44(2), 135–142. https://doi.org/10.3109/03009742.2014. 931457
(2) Weng, M. Y., Huang, Y. T., Liu, M. F., Lu, T. H. (2011). Incidence and mortality of treated primary Sjogren: syndrome in Taiwan: a popula- tion-based study. The Journal of rheumatology. 2011; 38(4), 706– 708.
(3) Maldini, C., Seror, R., Fain, O., Dhote, R., Amoura, Z., De Bandt, M. et al.; Epidemiology of primary Sjögren syndrome in a French multiracial/multiethnic area. Arthritis care & research. 2014; 66(3), 454–463.
(4) Nakamura H, Takahashi Y, Yamamoto-Fukuda T. Direct infection of primary salivary gland epithelial cells by human T lymphotropic virus type I in patients with Sjögren syndrome. Arthritis Rheumatol. 2015;67(4):1096-1106.
(5) Reveille, J. D., Wilson, R. W., Provost, T. T., Bias, W. B., Arnett, F. C. Primary Sjögren syndrome and other autoimmune diseases in families. Prevalence and immunogenetic studies in six kindreds. Annals of internal medicine. 1984;101(6), 748–756.
(6) Quartuccio, L., Isola, M., Corazza, L., Ramos-Casals, M., Retamozo, S., Ragab, G. M. et al. Validation of the classification criteria for cryoglobulinaemic vasculitis. Rheumatology (Oxford, England). 2014; 53(12), 2209–2213.
(7) Retamozo, S., Gheitasi, H., Quartuccio, L., Kostov, B., Corazza, L., Bové, A., Sisó-Almirall, A.,et al. Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients. Rheumatology (Oxford, England). 2016; 55(8), 1443–1451.
(8) Ramos-Casals, M., Solans, R., Rosas, J., Camps, M. T., Gil, A., Del Pino-Montes, J., et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine. 2008: 87(4), 210–219.
(9) Ramos-Casals, M., Tzioufas, A. G., Font, J. Primary Sjögren syn- drome: new clinical and therapeutic concepts.Annals of the rheumatic diseases. 2005; 64(3), 347–354.
(10) Kyriakidis, N. C., Kapsogeorgou, E. K., Gourzi, V. C., Konsta, O. D.,Baltatzis, G. E., Tzioufas, A. G. Toll-like receptor 3 stimulation promotes Ro52/TRIM21 synthesis and nuclear redistribution in salivary gland epithelial cells, partially via type I interferon pathway. Clinical and experimental immunology. 2014; 178(3), 548– 560.
(11) Hall, J. C., Casciola-Rosen, L., Berger, A. E., Kapsogeorgou, E. K., Cheadle, C., Tzioufas, A. G.,et al. Precise probes of type II inter- feron activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109 (43), 17609–17614.
(12) Nocturne, G., Mariette, X. Sjögren Syndrome-associated lympho- mas: an update on pathogenesis and management. British journal of haematology. 2015; 168(3), 317–327.
(13) Nocturne, G., Boudaoud, S., Miceli-Richard, C., Viengchareun, S., Lazure, T., Nititham, J., et al. Germline and somatic genetic varia- tions of TNFAIP3 in lymphoma complicating primary Sjogren syndrome. 2013; Blood, 122(25), 4068–4076.
(14) Fabini, G., Rutjes, S. A., Zimmermann, C., Pruijn, G. J., Steiner, G. Analysis of the molecular composition of Ro ribo nucleoprotein complexes. Identification of novel Y RNA-binding proteins. European journal of biochemistry. 2000; 267(9), 2778–2789.
(15) Mekinian, A., Nicaise-Roland, P., Chollet-Martin, S., Fain, O., & Crestani, B. (2013). Anti-SSA Ro52/Ro60 antibody testing by immunodot could help the diagnosis of Sjogren syndrome in the absence of anti-SSA/SSB antibodies by ELISA. Rheumatology. 2013; 52(12), 2223–2228.
(16) Seror, R., Ravaud, P., Bowman, S. J., Baron, G., Tzioufas, A., Theander, E. EULAR Sjogren syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren syndrome. Annals of the rheumatic diseases. 2010; 69(6), 1103–1109.
(17) Skopouli, F. N., Barbatis, C., Moutsopoulos, H. M. Liver involvement in primary Sjögren syndrome. British journal of rheumatology. 1994; 33(8), 745–748.
(18) Bartoloni, E., Baldini, C., Schillaci, G., Quartuccio, L., Priori, R., Carubbi, F., et al. Cardiovascular disease risk burden in primary Sjögren syndrome: results of a population-based multicentre cohort study. Journal of internal medicine. 2015; 278(2), 185–192.
(19) Lazarus, M. N., & Isenberg, D. A. Development of additional autoimmune diseases in a population of patients with primary Sjögren syndrome. Annals of the rheumatic diseases. 2005; 64(7), 1062–1064.
(20) Saito, T., Fukuda, H., Arisue, M., Matsuda, A., Shindoh, M., Amemiya, et al. Relationship between sialographic findings of parotid glands and histopathologic finding of labial glands in Sjögren syndrome. Relation to clinical and immunologic findings. Oral surgery, oral medicine, and oral pathology. 1991; 72(6), 675–680.
(21) Bowman, S. J., Pillemer, S., Jonsson, R., Asmussen, K., Vitali, C., Manthorpe, R., et al. Contributors to and participants at the work- shop. Revisiting Sjögren syndrome in the new millennium: perspectives on assessment and outcome measures. Report of a workshop held on 23 March 2000 at Oxford, UK. Rheumatology (Oxford, England). 2001; 40(10), 1180–1188.
(22) Seror, R., Gottenberg, J. E., Devauchelle-Pensec, V., Dubost, J. J., Le Guern, V., et al. Assessment of systemic disease activity is complementary to assessment of patients symptoms in primary Sjogren syndrome. Ann Rheum Dis. 2011; 70(Suppl 3), 505.
(23) Theander, E., Vasaitis, L., Baecklund, E., Nordmark, G., Warfvinge, G., Liedholm, R., et al. . Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren syndrome. Annals of the rheumatic diseases. 2011; 70(8), 1363–1368.